Genocea harnesses the immune system to reveal the optimal targets for each patient to develop cancer immunotherapies that we hope will be better, more accessible and more affordable.
- Year invested 2018
- Investment Stage Early
- Board Members
- Sectors
- Investment Status Current
- Website genocea.com
- Company Status IPO/Public (NASDAQ: GNCA)